Bacterial Infections after Burn Injuries: Impact of Multidrug Resistance by Lachiewicz, A.M. et al.
Bacterial Infections After Burn Injuries: Impact of 
Multidrug Resistance
Anne M. Lachiewicz,1 Christopher G. Hauck,1 David J. Weber,1 Bruce A. Cairns,2,3 and David van Duin1
1Division of Infectious Diseases and 2Department of Surgery, University of North Carolina at Chapel Hill, and 3North Carolina Jaycee Burn Center, Chapel Hill
Patients who are admitted to the hospital after sustaining a large burn injury are at high risk for developing hospital-associated infec-
tions. If patients survive the initial 72 hours after a burn injury, infections are the most common cause of death. Ventilator-associated 
pneumonia is the most important infection in this patient population. The risk of infections caused by multidrug-resistant bacterial 
pathogens increases with hospital length of stay in burn patients. In the first days of the postburn hospitalization, more susceptible, 
Gram-positive organisms predominate, whereas later more resistant Gram-negative organisms are found. These findings impact 
the choice of empiric antibiotics in critically ill burn patients. A proactive infection control approach is essential in burn units. 
Furthermore, a multidisciplinary approach to burn patients with a team that includes an infectious disease specialist and a pharma-
cist in addition to the burn surgeon is highly recommended.
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Burn injury is a frequent source of morbidity and mortality 
in the United States. In 2016, approximately 486 000 patients 
received medical care for burn injuries of whom approximately 
40 000 required hospitalization. Importantly, 3275 patient deaths 
were attributed to burn injuries [1]. Burn injury results in a state 
of immune system dysregulation that predisposes patients to 
infection. The most obvious effect is the loss of the natural cuta-
neous barrier. Beyond this is a more complex interplay of pro- 
and anti-inflammatory signals that result in dysregulation of the 
innate and adaptive immune responses [2]. Furthermore, inha-
lation injury, endotracheal intubation, central venous access, 
arterial lines, urinary catheters, and prolonged hospitalization 
all contribute to increased risk of infection in burn patients [3].
With advancements in burn care over the last 50 years, infec-
tion is now the leading cause of death after extensive burn 
injuries. Multiple studies over the last decade have shown that 
42%–65% of deaths in burn victims are attributable to infection 
[4–7]. In addition, burn patients with infections have more than 
twice the mortality rate of uninfected patients [8]. The preva-
lence of multidrug-resistant (MDR) bacteria in burn centers 
may result in the empiric selection of antibiotics that target 
MDR bacteria, thus propagating a vicious cycle of increased 
antimicrobial resistance. A multidisciplinary approach involv-
ing an infectious diseases physician and pharmacist working in 
collaboration with the burn surgeon may optimize care for this 
complex patient population.
COMMON INFECTIOUS SYNDROMES IN BURN 
PATIENTS
Infection is by far the most frequent complication encoun-
tered by patients with burn injuries. The 2016 National Burn 
Repository Report found that 7 of the 10 most frequent com-
plications occurring in the burn patient were of an infectious 
etiology, with pneumonia, urinary tract infection (UTI), and 
cellulitis topping the list [1]. Recognizing the limitations of data 
collated by the National Burn Repository (voluntary reporting 
from burn centers with no standardized definitions for infec-
tions), respiratory tract infections are most frequently reported. 
Contributing factors include the presence of inhalation injury in 
some patients and the frequent need for prolonged mechanical 
ventilation. From 2006 to 2016, pneumonia occurred in 5.4% of 
all patients presenting with fire/flame burns [1]. Urinary tract 
infection was the second most frequently reported infectious 
complication in burn patients; a UTI complicated the hospi-
tal course of 3.4% of patients with fire/flame burns. This risk 
is likely associated with prolonged hospitalization and the fre-
quent need for Foley catheters. Burn wound infection, septice-
mia, bacteremia, and miscellaneous other infections are among 
the other most frequent complications reported.
TIMELINE OF BACTERIAL INFECTION IN BURN 
PATIENTS
The pattern of hospital-associated infections (HAIs) in patients 
with burn injuries follows a relatively predictable timeline 
(Figure 1). Not surprisingly, skin and soft tissue infections occur 
earlier during hospitalization, generally during the first week. 
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In contrast, pneumonia, bloodstream infections, and urinary 
tract infections tend to occur later in the hospitalization, each 
with a median onset >30 days after admission [9]. Several stud-
ies have shown that the length of hospitalization after a burn 
injury is associated with the types of bacterial species that are 
isolated from patients. In a retrospective study of 125 burn 
patients admitted to a Canadian burn center (2010–2013), the 
association between time since admission and the distribution 
of Gram-negative isolates from clinical cultures was described. 
Of note, the main change was seen in the contribution of 
Pseudomonas aeruginosa. Within the first 7 days of admission, P. 
aeruginosa was rare, constituting only 8% of all Gram-negative 
isolates. After 28 days of hospitalization, this increased to 55%. 
A sharp decline meanwhile was seen for Haemophilus influen-
zae; from 36% within 7 days to virtually absent after 7 days [10]. 
A similar increase associated with longer length of stay and the 
incidence of positive cultures with P. aeruginosa was seen in a 
single-center study of 5524 burn patients admitted from 2004 to 
2013 [9]. In that same study, Gram-positive organisms tended 
to occur earlier during hospitalization as compared with Gram-
negative bacteria. For instance, the median time from admission 
to first positive culture was 3 days (interquartile range [IQR], 
2–8 days) for Staphylococcus aureus versus 18 days (IQR, 9–36 
days) for P. aeruginosa [9].
ANTIMICROBIAL-RESISTANT BACTERIAL 
PATHOGENS IN BURN PATIENTS
Pathogens of specific concern in the burn population 
include MDR strains of P.  aeruginosa, Acinetobacter bau-
mannii, and Stenotrophomonas maltophilia and methicillin 
resistant S. aureus (MRSA). Outbreaks with carbapenem-resist-
ant Enterobacteriaceae in burn units have also been described 
[11]. A  single-center study from 2008 to 2012 reported rates 
of multidrug resistance in bacteria causing HAIs, as defined 
by the Centers for Disease Control and Prevention, of 33.8%, 
90.8%, 21.1%, and 82% in Pseudomonas spp., A.  baumannii, 
S. maltophilia, and S. aureus, respectively [12]. Focusing on res-
piratory isolates, a comparison of rates of multidrug resistance
within intensive care units found 41% of burn intensive care unit
respiratory isolates were MDR, whereas only 14% of isolates from 
other intensive care units in the same hospital were MDR [13].
A 2007 study in Miami revealed similarly alarming rates of MDR 
Acinetobacter spp., with 87% being both imipenem resistant and
MDR [14]. Researchers from the military burn center at the
Brooke Army Medical Center in Texas reported less dramatic but 
quite significant rates of MDR pathogens: 15% of Pseudomonas
spp., 53% of Acinetobacter spp., and 34% of S. aureus [15].
RISK FACTORS FOR ACQUISITION OF MULTIDRUG-
RESISTANT BACTERIA IN BURN PATIENTS
Although length of hospital stay in patients admitted for burn 
injury is obviously associated with various clinical characteristics 
such as burn size and the presence of inhalational injury, burn 
center length of stay is also a major risk factor for infection with 
MDR bacteria. For instance, in the above-mentioned Canadian 
study of 125 patients, 6% of bacterial species isolated during the 
first 7 days were MDR as compared with 44% after 28 days of 
hospitalization [10]. Furthermore, in the previously cited study 
of >5000 burn patients, the rates of MDR Gram-negative bac-
teria increased sharply during hospitalization [9]. From the first 
week of admission to week 4 or later, rate of Enterobacteriaceae 
per 1000 patient-days increased from 0.04 to 0.82 for carbapen-
em-resistant Enterobacteriaceae, 0.26 to 0.46 for extended-spec-
trum β-lactamase-producing Enterobacteriaceae, and 0.52 to 
2.61 for fluoroquinolone-resistant Enterobacteriaceae. The rate 
of MDR Pseudomonas spp. similarly increased from 0.04 per 
1000 patient-days in the first week to 1.85 per 1000 patient-days 
in the 4th week and later of admission [9].
In addition, risk factors that have been described in other 
populations for the acquisition of MDR organisms have also 
been reported for the burn population [16, 17]. Most impor-
tant among these are previous antibiotic exposure and the use 
of invasive medical devices such as endotracheal tubes and uri-
nary catheters.
PREVENTION OF MULTIDRUG-RESISTANT 
BACTERIAL INFECTIONS IN BURN PATIENTS
Infection prevention through a number of different strategies 
has been integral in the improvement of outcomes in patients 
with burn injuries (Table 1). As a consequence of prolonged 
hospitalizations and frequent invasive procedures, burn 
patients are at high risk for nosocomial infections. Infection 
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Figure 1. Timeline of common infections and pathogens after burn injury [9, 10]. 
Shown is the relative incidence over time of various common hospital-associated 
infections as well as common pathogens. Darker shading indicates increased rel-
ative incidence.
control procedures such as hand hygiene, contact isolation, 
and environmental cleaning/disinfection are vital to reducing 
incidence of HAIs [18–20]. Multiple studies have shown the 
benefit of infection control strategies in preventing the spread 
of MDR organisms in burn patients [21, 22]. However, shared 
resources that are used in the care of multiple patients such as 
the hydrotherapy room (also known as the “tank room”) com-
plicate the implementation of strict infection control measures. 
In a sustained outbreak of MDR P. aeruginosa in a Swiss burn 
unit, a cluster of 23 infected patients who were cared for over 
3 years shared the same P. aeruginosa genotype (DLST 1–18). 
This genotype was also recovered from 2 hydrotherapy rooms 
in which 19 of the 23 infected patients had been treated, and the 
outbreak was controlled by instituting environmental cleaning/
disinfection procedures aimed primarily at the hydrotherapy 
room [23].
A variety of practices have been used for screening for 
MDR organisms in burn units, including weekly surveillance 
for MRSA and vancomycin-resistant Enterococci and out-
break-guided surveillance [11, 24]. An approach of thrice 
weekly endotracheal aspirate surveillance cultures in patients 
with inhalation injury was reported to predict MDR organisms 
in subsequent ventilator-associated pneumonia (VAP) with a 
sensitivity of 83% and specificity of 96% [25]. Although more 
data are still needed to define whether active surveillance cul-
tures should be instituted routinely in burn centers, the high 
rates of MDR organisms in burn units warrant careful con-
sideration of the costs, risks, and benefits of various screening 
approaches.
Management of intravascular catheters in the burn pop-
ulation is a controversial topic. Although guidelines from 
the Society for Healthcare Epidemiology of America and the 
Infectious Diseases Society of America recommend that cen-
tral venous catheters should not be routinely replaced, most 
burn units use this practice, based on a scarcity of data in the 
burn population [26, 27]. A  single center study performed 
in 2000–2001 compared patients (n  =  17) in whom central 
venous catheters were replaced every 4th day with histori-
cal controls (n  =  38), who underwent every 3rd day routine 
replacement [28]. The number of catheter-related bloodstream 
infections (defined as those bacteremias in which the causa-
tive organism was also grown from a catheter segment culture) 
increased from 0.18 per patient in the every 3rd day historical 
control group to 1.18 per patient in the every 4th day group 
[28]. Another study looked at increasing time between line 
exchanges from every 48 hours to every 72 hours and found 
no increase in rates of line-related infections [29]. Based on 
these limited studies, many burn units perform routine line 
exchanges every 72 hours. Clearly, a multicenter, randomized 
controlled trial is needed to determine whether any routine 
changes are indicated in this population and, if so, to deter-
mine the appropriate interval between line exchanges.
From a surgical perspective, early excision of burn wounds 
and grafting of full thickness burns has been found to signifi-
cantly decrease rates of mortality and may also reduce the inci-
dence of infection [30]. In addition, meticulous wound care 
focusing on removal of devitalized tissue should be performed as 
a routine part of the care of patients with burn wounds. Topical 
antimicrobials such as mafenide and silver sulfadiazine, in com-
bination with early excision, have been associated with a decline 
in the incidence of sepsis due to burn wound infections [31]. 
Prophylactic systemic antibiotics to prevent infection have not 
been shown to be efficacious in multiple studies in burn patients. 
A Cochrane review in 2013 evaluated 36 studies and concluded 
there was not sufficient evidence to recommend their usage [32]. 
However, a retrospective Japanese study in 2016 found that using 
either a first-generation cephalosporin or ampicillin/sulbactam 
as prophylaxis improved 28-day mortality in patients with severe 
burns who required mechanical ventilation [33]. If confirmed 
in other independent studies, these results raise the possibil-
ity that prophylaxis may be useful in a subset of burn patients. 
Currently, however, systemic prophylactic antibiotics are not 
recommended by the International Society for Burn Injury [34]. 
Data regarding the utility of routine perioperative antibiotics in 
burn management are also inconclusive, but experts suggest that 
the use of perioperative antibiotics for excision and grafting pro-
cedures may be considered [35].
DIAGNOSIS OF MULTIDRUG-RESISTANT BACTERIAL 
INFECTIONS IN BURN PATIENTS
As in other critically ill populations, the main challenge in the 
diagnosis of MDR bacterial infection in burn patients is mak-
ing the distinction between infection and colonization (Table 
1). Colonization tends to precede infection, and often a clear 
transition point from one state into the next is not clinically 
apparent. Patients who undergo prolonged mechanical ventila-
tion, which is quite common after a large burn, will inevitably 
develop respiratory tract colonization as well as endotracheal 
or tracheostomy tube colonization. Similarly, urinary bacter-
ial colonization is almost universal in the setting of long-term 
in-dwelling uretheral catheterization. Unfortunately, most 
patients with large burns are critically ill and are unable to 
provide clinical information, which is so crucial in diagnosing 
infection.
Both inhalation injury and acute respiratory distress syn-
drome secondary to burn injury complicate the diagnosis of 
VAP. An analysis of National Burn Repository data found that 
among patients with inhalation injury and pneumonia, those 
who underwent bronchoscopy, compared with patients who did 
not, had an 18% reduced risk of death [36]. However, the bene-
fit of preforming bronchoscopy in all burn patients to diagno-
sis pneumonia is less clear [37]. Detecting an MDR organism 
causing VAP with bronchoscopy at time of diagnosis or after 
4 days of treatment may assist in deciding on the duration of 
antimicrobial therapy, allowing less virulent organisms to be 
treated with a shorter duration of antibiotics [38].
Burn cellulitis and invasive burn wound infection can be dif-
ficult to distinguish from noninfectious burn erythema. Tissue 
biopsy for histology, which is often not performed due to labor 
and cost, remains the gold standard for diagnosis of invasive 
wound infection [39]. Methods for semiquantitative surface 
swab cultures and quantitative tissue biopsy culture have been 
well-described for burn patients, and historically high bacter-
ial counts have been used to define infection in some studies 
[39]. Some experts recommend performing routine infection 
surveillance of burn wounds using swab cultures for excised 
burns and areas of skin too thin to biopsy and biopsy for tissue 
below eschars [39]. However, one study team demonstrated that 
a single quantitative swab or biopsy may not be representative 
of all pathogens involved. The same investigators found that 
neither quantitative bacterial counts from swabs nor biopsies 
at the time of excision or dressing change were able to predict 
graft loss, bacteremia within 1 hour of wound manipulation, or 
clinical failure (defined as need for antibiotics within 72 hours, 
new appearance of fever, rigors, hypotension, or graft loss) [40, 
41]. Based on such findings, swab cultures and biopsies should 
probably be limited to patients with changes in wound appear-
ance or signs of systemic infection to avoid missing a source of 
infection, especially one caused by an MDR organism.
Recognizing sepsis in the burn population is also challeng-
ing because other systemic indicators of infection such as fever, 
hypotension, and elevated peripheral blood white blood cell 
count are quite common in uninfected burn patients [42]. In 
2007, the American Burn Association Consensus Conference 
to Define Sepsis and Infection in Burns defined sepsis as a 
documented infection plus 3 of 6 triggers (hyper/hypother-
mia, tachycardia, tachypnea, thrombocytopenia, hyperglyce-
mia, and inability to tolerate enteral feeding). The committee 
promoted the modified Marshall multiple organ dysfunction 
scoring system (after day 3 postburn) as the best tool for recog-
nizing sepsis-related organ dysfunction in burn patients [43]. 
However, because no criteria for sepsis have performed satis-
factorily in clinical studies of burn patients, the search contin-
ues 10 years later for the best strategy to diagnosis sepsis in this 
population [44].
The measurement of procalcitonin may show promise in 
diagnosis of sepsis in burn patients, although its exact role 
remains to be determined [45]. The introduction of a procalci-
tonin-based antibiotic algorithm resulted in antibiotic therapy 
being discontinued 5 days earlier, on average, in a small obser-
vational study [46]. Given the high incidence of MDR bacter-
ial infections, rapid diagnostics that indicate the presence or 
absence of MDR phenotype have great potential in the burn 
population. These may be used as screening tools for MDR 
bacterial carriage, as well as for rapid diagnosis of MDR bac-
terial infection.
TREATMENT OF MULTIDRUG-RESISTANT BACTERIAL 
INFECTIONS IN BURN PATIENTS
Once the decision is made to treat a burn patient with suspected 
or confirmed MDR bacterial infection, a number of specific 
issues should be taken into account. As in all infected patients, 
timely source control when feasible is crucial. For example, in 
patients with burn wound cellulitis and deeper skin and soft 
tissue infections, excision of the burn eschar will usually lead 
to rapid resolution of the infection [47]. Similarly, the prompt 
removal of infected catheters, especially infection with bio-
film-producing pathogens, is recommended to improve out-
comes [48, 49].
Knowledge of the local burn unit antibiogram, which may 
be quite different from the rest of the hospital, is essential for 
the optimization of empirical antibiotics [50]. At the same time, 
involvement of an antimicrobial stewardship program (ASP) 
is highly recommended to limit antibiotic exposure in patients 
when antibiotics are not necessary and therefore prevent future 
infection with MDR bacteria [34, 51]. The results of a recent sys-
tematic review of inpatient ASPs suggest that ASPs can improve 
prescribing and institutional resistance patterns without a large 
negative impact on patient outcomes [52]. The International 
Society for Burn Injury practice guidelines recommend that 
burn centers develop, implement, and monitor a local ASP, 
which will allow for investigation of patient and microbial resist-
ance outcomes of ASPs specifically in burn populations [34].
Antibiotic dosing in patients with large burn injuries is compli-
cated by a hyperdynamic state that often results in increased renal 
clearance of commonly used antibiotics [53, 54]. This hyperdy-
namic state displays high intrapatient and interpatient variability; 
therefore, patients may require higher than usual or more frequent 
antibiotic doses. Cota et al reviewed available data and modeling 
to derive evidence-based dosing for 15 antibiotics for patients with 
≥20% total body surface area- burn and normal renal function 
after 48 hours of admission [53]. Clearly, inclusion of a dedicated 
pharmacist in the multidisciplinary burn team is advisable.
Similar to other populations, a number of questions regard-
ing MDR bacterial infection treatment remain unanswered in 
burn patients. These include the impact of combination therapy 
on outcomes as well as on subsequent resistance development. 
Also, the role of newer agents directed at MDR bacteria such 
as novel cephalosporins, cephalosporin/β-lactamase inhibitor 
combinations, long-acting anti-MRSA antibiotics, and others, 
remains to be determined in the burn population.
CONCLUSIONS
Patients who have sustained a large burn injury are at risk 
for HAIs. With increasing duration of hospitalization, they 
are at increasing risk of MDR bacterial infections. The high 
prevalence of MDR bacteria in burn units is likely a conse-
quence of several factors, including high antibiotic pressures, 
high colonization pressures, need for intensive medical and 
surgical therapy, and a vulnerable, immunocompromised 
patient population. Prevention of spread of MDR bacteria in 
this population similarly needs to consist of a multipronged 
approach that includes hand hygiene, antibacterial steward-
ship, optimization of surgical interventions, thoughtful use 
of medical devices, and environmental control. Involvement 
of an infectious diseases specialist in this process as well as 
in the day-to-day care of these complex patients is highly 
recommended. 
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